EC Healthcare provided sales guidance for the year ended 31 March, 2022. For the year, the Group expects to record sales volume of no less than HKD 3,000 million, representing an increase of no less than 35% as compared with the same period last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 HKD | +0.81% | +5.04% | -28.16% |
Jan. 31 | EC Healthcare Announces Change of Principal Place of Business in Hong Kong, with Effect from 1 February 2024 | CI |
Jan. 24 | EC Healthcare's Overall Sales Volume Rises 7% in Q4 2023 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.16% | 188M | |
+34.84% | 442M | |
-28.48% | 375M | |
+10.34% | 295M | |
-25.13% | 96.48M | |
-3.44% | 81.2M | |
-7.59% | 68.4M | |
-26.23% | 64.76M | |
0.00% | 61.81M | |
-30.86% | 58.39M |
- Stock Market
- Equities
- 2138 Stock
- News EC Healthcare
- EC Healthcare Provides Sales Guidance for the Year Ended 31 March, 2022